According to a new report published by Allied Market Research, titled, “Epigenetics Market by Product, Application, End User: Opportunity Analysis and Industry Forecast, 2020–2027," the global epigenetics market was valued at $772 million in 2019, and is projected to reach $2,168 million by 2027, registering a CAGR of 13.6% from 2020 to 2027.
Epigenetics is an area of developmental biology that involves study of cellular and physiological trait variations initiated by external or ecological aspects. This external stimulus turns genes “on” and “off” and affects ability of cells to read genes. Epigenetics changes an organisms’ phenotype rather than genotype, wherein the underlying DNA or RNA sequence remains unchanged. For instance, DNA methylation and histone modification are epigenetic processes wherein the alteration in gene expression is observed without change in the DNA sequence. Increase in use and application of epigenetics to formulate drugs to treat different oncology and non-oncology-related diseases is expected to boost the epigenetics market growth.
Rise in cancer prevalence; increase in funding & aids for R&D activities; rise in partnership between academic, pharmaceutical, & biotechnology companies for epigenetics studies; and increase in application of epigenetics in non-oncology diseases majorly drives the market growth. However, high cost of instruments and lack of trained professionals are factors that impede the epigenetics market growth. Furthermore, growth opportunities in emerging markets provide lucrative opportunities to the market players.
On the basis of product, the kits & assays product segment occupied the highest share in the epigenetics market, owing to their sheer usage, need throughout the protocol, and other pre-requisite steps of DNA analysis.
On the basis of application, the oncology segment dominates the application segment in 2019, and is expected to grow at a CAGR of 13.3% during the forecast period. Increase in adoption of epigenetics for oncology, higher number of R&D activities, and availability of wide variety of products majorly fuel the epigenetics market growth.
On 11th March 2020, the World Health Organization made an assessment that COVID-19 can be characterized as a pandemic. In addition, there are no drugs that are currently licensed for the treatment of COVID-19 treatment or prevention. Combination therapies reduce drug resistance, suppress viral replication, lower toxicity levels, and provide synergistic effects. Although there is no clinically approved drug or vaccine available to be used against coronavirus infection, few therapeutic combinations have been evaluated to survive this viral infection. Use of targeted antiviral therapies such as remdesivir, rapamycin, ribavirin, and other epigenetic drugs such as BRD4 inhibitors, DNMT1 inhibitors, and HDAC inhibitors have been demonstrated to potentially inhibit the virus function. Epigenetic dysregulation may facilitate viral entry and an excessive immune response and epigenetic control of ACE2 can be a viable method for prevention and therapy of COVID-19. Thus, with increase in number of epigenetic researches and rise in awareness of epigenetic drugs, treatment of coronavirus infection is expected to positively impact the epigenetics market growth.
Key Findings Of The Study
- By product type, the kits segment held nearly one third share in the global market in 2019.
- By application, the non-oncology segment exhibits fastest growth, and is expected to grow at a CAGR of 14.2% from 2020 to 2027.
- By end user, the pharmaceutical & biotechnology companies segment held the largest market share in 2019, and is expected to remain dominant throughout the forecast period.
- By region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 14.7% during the forecast period.
North America accounted for more than one third of the global epigenetics market share in 2019, and is expected to remain dominant throughout the forecast period. This is attributed to developed healthcare infrastructure, wide availability of advanced epigenetics products, large presence of key players, and presence of trained medical professionals. However, Asia-Pacific is expected to witness highest growth rate during the forecast period, attributable to rise in awareness related to epigenetics, increase in penetration of key players in emerging countries in Asia-pacific, and development in infrastructure for research and clinical settings.